Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer
AUTOR(ES)
Mellado, B
FONTE
Nature Publishing Group
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2768456Documentos Relacionados
- Pelvic lymph node dissection in high-risk prostate cancer
- Radical prostatectomy for high-risk prostate cancer | Opinion: YES
- Radical prostatectomy for high-risk prostate cancer | Opinion: NO
- Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients.
- Plasma Selenium, Manganese Superoxide Dismutase, and Intermediate- or High-Risk Prostate Cancer